Core Viewpoint - BioPorto A/S will present its financial results for the first half of 2025 during an investor webcast scheduled for August 15, 2025 [1] Company Overview - BioPorto A/S is an in vitro diagnostics company focused on improving patient management through actionable biomarkers [2] - The company specializes in antibody and assay development, aiming to address significant unmet medical needs with its product pipeline [2] Key Products - The flagship products of BioPorto are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of Acute Kidney Injury (AKI) [3] - NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier intervention [3] Market Presence - BioPorto has facilities located in Copenhagen, Denmark, and Boston, MA, USA, and its shares are listed on the Nasdaq Copenhagen stock exchange [4]

Core Viewpoint - BioPorto A/S has announced the appointment of Carsten Buhl as the new CEO, effective September 1, 2025, as part of its succession planning strategy [1][2]. Company Leadership Transition - Current CEO Peter Mørch Eriksen will remain in his position until September 1, 2025, and will assist Carsten Buhl during the transition period [2]. - Carsten Buhl has over 25 years of experience in the MedTech/life science industries, previously serving as President of Americas at WSAudiology and holding senior leadership roles at Natus Medical Inc, Ambu, and GN Store Nord [3]. Strategic Goals and Future Plans - Jens Due Olsen, Chair of BioPorto, emphasized that Carsten Buhl will play a crucial role in launching ProNephro AKI (NGAL)™ in the US market, driving revenue growth, and finalizing clinical studies for an FDA application for adult use in 2026 [4]. - Carsten Buhl expressed enthusiasm about joining BioPorto and aims to unlock the full potential of the company's biomarker tests for kidney health, which can enhance clinical and economic outcomes globally [4]. Company Achievements - Under Peter Mørch Eriksen's leadership, BioPorto achieved significant milestones, including the development of a comprehensive Corporate Strategy Plan, revenue growth, preparation for the commercial launch of ProNephro AKI (NGAL) in the US, and securing critical financing rounds [4]. Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable biomarkers to improve patient management and outcomes [5]. - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), enabling earlier intervention and tailored patient management strategies [6].

Core Viewpoint - BioPorto A/S has issued 1,700,000 warrants to its Board of Directors as part of their remuneration, with each warrant allowing the purchase of one share at an exercise price of DKK 1.50, reflecting the current closing price on Nasdaq Copenhagen [1][2]. Summary by Sections Warrants Issuance - The issuance of warrants was approved during the annual general meeting on April 11, 2025, and is part of the company's compensation strategy for its Board members [1]. - The warrants will vest in equal tranches quarterly over a two-year period, with the first tranche becoming available at the start of the first calendar quarter following the grant date [3]. Terms and Conditions - The warrants are governed by the company's incentive warrant program and include provisions for claw-back in cases of erroneous financial information and accelerated vesting in the event of a takeover or business combination [4]. - The theoretical market value of the newly issued warrants is calculated to be DKK 1,843,580, based on the Black-Scholes formula, with an interest rate of 2.37% and historical volatility of 63.82% over 120 months [5]. Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable biomarkers to enhance patient management and improve clinical outcomes [7]. - The company's flagship products utilize the NGAL biomarker to assist in the risk assessment and diagnosis of Acute Kidney Injury (AKI), enabling faster identification and intervention for at-risk patients [8]. - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [9].

Core Viewpoint - BioPorto A/S is set to present its financial results for Q1 2025 during a webcast on May 8, 2025, highlighting its focus on early detection of Acute Kidney Injury (AKI) [1] Company Overview - BioPorto A/S specializes in in vitro diagnostics aimed at improving early detection of AKI, utilizing actionable biomarkers to enhance patient management [2][3] - The company leverages its expertise in antibodies and assay development to create innovative products addressing significant unmet medical needs [2] Product Information - The flagship products of BioPorto are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of AKI, a condition that can lead to severe health consequences if not treated promptly [3] - NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier interventions and tailored management strategies [3] Company Facilities and Stock Information - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [4]